Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts  by Molden, Tor et al.
Papillomavirus Research 2 (2016) 153–158Contents lists available at ScienceDirectPapillomavirus Researchhttp://d
2405-85
n Corr
E-m
berit.fei
irene.kr
mona.li
roger.m
christin
lill.trogs
1 Sh
2 Prjournal homepage: www.elsevier.com/locate/pvrHuman papillomavirus prevalence and type distribution in urine
samples from Norwegian women aged 17 and 21 years: A nationwide
cross-sectional study of three non-vaccinated birth cohorts
Tor Molden a,n, Berit Feiring a, Ole Herman Ambur b, Irene K. Christiansen b, Mona Hansen b,
Ida Laake a, Roger Meisal b, Ellen Myrvang b, Christine Monceyron Jonassen b,c,1,2,
Lill Trogstad a,1
a Norwegian Institute of Public Health, PO Box, 4404 Nydalen, 0403 Oslo, Norway
b Akershus University Hospital, PO Box 1000, 1478 Lørenskog, Norway
c Østfold Hospital Trust, PO Box 300, 1714 Grålum, Norwaya r t i c l e i n f o
Article history:
Received 19 February 2016
Received in revised form
6 May 2016
Accepted 7 May 2016
Available online 20 May 2016
Keywords:
Human papillomavirus
Immunization
Urine
Vaccine
HPV prevalence
HPV genotypex.doi.org/10.1016/j.pvr.2016.05.002
21/& 2016 Published by Elsevier B.V. This is a
esponding author.
ail addresses: tor.molden@fhi.no (T. Molden),
ring@fhi.no (B. Feiring), ole.herman.ambur@a
aus.christiansen@ahus.no (I.K. Christiansen),
ndsethmo.hansen@ahus.no (M. Hansen), ida.la
eisal@ahus.no (R. Meisal), ellen.myrvang@ahu
e.monceyron.jonassen@so-hf.no (C.M. Jonasse
tad@fhi.no (L. Trogstad).
ared authorship.
esent address.a b s t r a c t
Background: The aim of the current study was to assess the HPV prevalence in unscreened and un-
vaccinated young women living in Norway, to provide important baseline data for early estimation of the
impact of the HPV vaccination program.
Methods: A total of 13,129 self-sampled urine samples from two complete birth-cohorts of 17-year old
women born in 1994 and 1996 and one third of a birth-cohort of 21-year old women born in 1990, were
analysed for the presence of 37 HPV types using PCR and a DNA hybridization technique.
Results: In the two birth cohorts of 17-year old women, HPV was detected in 19.9% (95% CI 18.8–20.9) and
15.4% (95% CI 14.5–16.3), respectively. High-risk HPV types were detected in 11.2% (95% CI 10.3–12.0) and
7.6% (95% CI 6.9–8.2), respectively, while vaccine types were detected in 7.4% (95% CI 6.7–8.1) and 6.0%
(95% CI 5.4–6.6), respectively. Among the 21-year old women HPV was detected in 45.4% (95% CI 42.9–
47.8), whereas high-risk types were detected in 29.8% (95% CI 27.5–32.0). Vaccine types (HPV 6, 11, 16, 18)
were detected in 16.2% (95% CI 14.4–18.1).
Conclusion: This large population based study conﬁrms that HPV testing in urine samples is easy and
highly feasible for epidemiological studies and vaccine surveillance in young women. HPV was very
common and a broad spectrum of HPV types was identiﬁed. Differences in HPV prevalence was seen both
between age groups and between the two birth cohorts of 17-year old women.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infection with an oncogenic type of human papillomavirus
(HPV) is a pre-requisite for developing cervical pre-cancerous le-
sions and carcinomas. More than 40 HPV types are known to infect
the human anogenital tract. At least 12 types are consideredn open access article under the C
hus.no (O.H. Ambur),
ake@fhi.no (I. Laake),
s.no (E. Myrvang),
n),carcinogenic and are commonly referred to as high-risk types [1–
3].
Vaccination against HPV infection was introduced in the Nor-
wegian childhood immunization program in the school year 2009/
2010. All girls born in 1997 and later have been offered the vaccine
in the 7th grade at age 11–12 years. No publically funded catch-up
vaccination for the older age groups has been introduced. The
4-valent vaccine, Gardasils is used in the program. The vaccine
offers protection against HPV 16 and 18, which cause about 70% of
invasive cervical carcinomas [4], as well as the low-risk types 6, 11,
the main etiologic agent for external genital warts [5,6].
Knowledge of the baseline HPV prevalence and type distribu-
tion in unscreened and unvaccinated birth cohorts is essential for
estimating the impact of HPV vaccination. However, few popula-
tion-based studies have been conducted to assess the prevalence
of HPV and type distribution in pre-teens or young adults. SmallerC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lands show an HPV prevalence in urine of4.4–32.2% in the age
groups of 14–16 and 20–21 years, respectively [7,8]. A few studies
have assessed the prevalence of circulating HPV types in Norway,
generally focusing on HPV types present in cervical precancerous
or cancerous lesions or in women visiting gynaecology clinics [9–
15]. Less is known about the HPV prevalence and genotype dis-
tribution in women in their late teens or early twenties, who have
not yet been invited to participate in the national screening pro-
gram against cervical cancer. The aim of the current study was to
describe the HPV type prevalence in young women in Norway who
have not been offered the vaccine against HPV as part of the na-
tional childhood immunization program. We were also interested
in comparing the HPV prevalence between 17-year olds and 21-
year olds and between two birth cohorts of 17-year olds to
document natural ﬂuctuations of HPV prevalence.2. Material and methods
2.1. Enrolment, sample collection, and study sample
Women eligible for the study were identiﬁed through the
Norwegian Population Register.
In 2011, an invitation letter was sent to all women born in 1994
residing in Norway as of January 1st 2011, except some born at the
end of 1994, in total 83.0% of the birth cohort (Fig. 1). In 2013, a
total of 99.5% of the women born in 1996 were invited to parti-
cipate in the study. The invitation was sent the same month the
women became 17 years (in 2011 and 2013, respectively). Women
born between August and December in 1990 were invited in the
period January to May 2012. The HPV prevalence in this age-group
was expected to be at least twice the HPV prevalence in the 17-
year olds. Therefore, only women born between August and De-
cember were invited, in total 30.8% of the birth cohort. From the
initial birth cohort list obtained at the beginning of the year of
sample collection, some were not invited due to missing address,
invalid social security number, death, or emigration.
The invitation was sent by mail and included information about
the study, an informed consent form, and a pre-franked envelope
for returning the signed informed consent. Womenwho consented
to participate received a sample kit and instructions for obtaining
a ﬁrst void urine sample together with a pre-franked return en-
velope. The sample device contained a preservative (boric acid), to
prevent bacterial growth. The urine samples were shipped by mail
to the Norwegian Institute of Public Health (NIPH) where the
samples were marked, processed and stored at 80 °C until fur-
ther analysis. An aliquot was sent to the Norwegian HPV ReferenceFig. 1. Flow-chart study population. 1,2,3Total female birth cohorLaboratory (Akershus University Hospital) for isolation of nucleic
acids and HPV genotyping. HPV results were not routinely com-
municated to the participants, but were provided upon request.
Participants could withdraw from the study at any time. All par-
ticipants were rewarded with two cinema tickets for their
contribution.
A total of 13,129 women contributed with a urine sample. The
participation rates were similar for the northern, middle, western,
southern and eastern region of Norway, and ranged from 14.2 to
17.8% for the 21-year olds and 16.9–22.3% for the 17-year olds.
Linkage to the immunization register for individual vaccination
status was not performed since the current study population is
largely unvaccinated. These young women were not offered vac-
cine against HPV as part of the national immunization program.
According to distribution numbers, very few vaccine doses have
been distributed for sale to this group.
The study was approved by the Regional Committee for Med-
ical and Health Research Ethics and the Norwegian Data Protection
Authority.
2.1.1. Isolation of nucleic acids
Nucleic acids were isolated using Boom's isolation method [16]
and the automatic NucliSENS easyMAG extraction device (bio-
Mérieux Corporate, Marcy l’Etoile, France). Total nucleic acids were
kept cold and analysed within four hours or stored at 80 °C until
analysis.
Validation of sample adequacy and HPV genotyping
Human β-globin quantitative real-time PCR for validation of
sample adequacy and HPV genotyping using PCR and DNA hy-
bridization and Luminex based technology was performed as
previously described [17,18]. The HPV genotyping method detects
37 HPV types; 12 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59), six probable high-risk types (26, 53, 66, 68, 73, 82),
and 19 undetermined or low-risk types (6, 11, 30, 40, 42, 43, 54, 61,
67, 69, 70, 74, 81, 83, 86, 87, 89, 90, 91)[1,2].
In order not to compete with the HPV PCR, the β-globin PCR
was run in a separate reaction. The PCR products were kept frozen
at 20 °C until further analysis.
Upon Luminex detection of values in the range from the cut-off
value up to two times the cut-off value for any HPV-type, a re-
analysis was performed in duplicate. Individual cut-off values for
each HPV-type were calculated for each run based on the level of
background noise. Cut-off modiﬁcation values and factors for
cross-hybridization correction used to calculate the cut-off were
adapted from the WHO HPV reference laboratory in Sweden. A
total of 202 samples (1.5%) did not give a valid result for β-globin
or for HPV, and were excluded from the analyses.t alive the 1st of January the year of sample collection [29].
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The prevalence of HPV types was deﬁned as the number of
positive specimens divided by the total number of specimens with
valid PCR result (β-globin and Luminex). We calculated the cor-
responding 95% Wald conﬁdence intervals (CIs).
Chi squared tests were used to test for differences between
proportions. All tests were two-sided, and po0.05 was considered
statistically signiﬁcant. The data were analysed with STATA/SE
version 13.0 (StataCorp, College Station, Texas, USA).3. Results
HPV prevalence by birth cohort is shown in Table 1. The overall
HPV prevalence in urine specimens from 21-year old women was
45.4% (95% CI 42.9, 47.8). High-risk types were detected in 29.8%
(95% CI 27.5, 32.0), corresponding to 65.5% of all HPV positive
samples. The vaccine types 6, 11, 16, and 18, were detected in 16.2%
(95% CI 14.4, 18.1), corresponding to 35.7% of all HPV positive
samples. Multiple infections were observed in 26.1% (95% CI 23.9,
28.2).
For 17-year old women born in 1994, the overall HPV pre-
valence was 19.9% (95% CI 18.8, 20.9). High-risk types were de-
tected in 11.2% (95% CI 10.3, 12.0). Vaccine types 6, 11, 16, and 18,
were detected in 7.4% (95% CI 6.7, 8.1). Multiple infections were
observed in 9.2% (95% CI 8.5, 10.0). Among all positive HPV sam-
ples, 56.2% were high-risk types and 37.1% were positive for any
vaccine type.
For 17-year old women born in 1996, the overall HPV pre-
valence was 15.4% (95% CI 14.5, 16.3). High-risk types were de-
tected in 7.6% (95% CI 6.9, 8.2). Vaccine types 6, 11, 16, and 18, were
detected in 4.8% (95% CI 4.3, 5.3). Multiple infections were ob-
served in 6.0% (95% CI 5.4, 6.6). Among all HPV positive samples,
49.1% were positive for high-risk types, and 31.2% were positive for
any vaccine types.
The HPV prevalence was signiﬁcantly higher (po0.001) in 21-
year old women as compared to the 17-year old women combined
for HPV overall (45.4% vs. 17.5%), high-risk HPV types (29.8% vs.
9.3%), probable high-risk HPV types (8.2% vs. 3.1%), low-risk HPV
types (29.1% vs. 10.0%), vaccine HPV types (16.2% vs. 6.0%), and
multiple infections (26.1% vs. 7.5%). Moreover, the prevalence was
signiﬁcantly higher (po0.001) among 17-year olds born in 1994
than 17-year olds born in 1996 for HPV total, high-risk HPV types,
low-risk HPV types, vaccine HPV types, and multiple infections,
whereas the prevalence of probable high-risk types was not sig-
niﬁcantly different (p¼0.45).Table 1.
HPV prevalence in urine samples from Norwegian women by birth cohort.
21 yr 1990 (N¼1565) 17 y
HPV n % (95% CI) n
Totala 710 45.4 (42.9–47.8) 1087
High-risk (HR)b 466 29.8 (27.5–32.0) 611
Probably HRc 129 8.2 (6.9–9.6) 174
Low-riskd 455 29.1 (26.8–31.3) 640
Vaccine typese 254 16.2 (14.4–18.1) 403
Multiple infectionf 408 26.1 (23.9–28.2) 504
Wald's method was used to calculate 95% CIs.
a HPV total includes those who are positive for at least one of the 37 HPV types te
primers.
b HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59.
c HPV types 26, 53, 66, 68, 73, 82.
d HPV types 6, 11, 30, 40, 42, 43, 54, 61, 67, 69, 70, 74, 81, 83, 86, 87, 89, 90, 91.
e HPV types 6, 11, 16, 18.
f Infection positive for two or more HPV types.The prevalence of HPV types deﬁned as high-risk or probable
high-risk are presented in Fig. 2. HPV 16 was the most common
HPV genotype detected in 21-year old women, with a prevalence
of 11.4%. Following HPV 16, the four most common high-risk or
probable high-risk HPV types were in decreasing order; HPV 51,
56, 18, and 31.
Among 17-year old women born in 1994, HPV 16, the most
common HPV type, was detected in 3.5% of the samples. After HPV
16, the four most common high-risk or probable high-risk HPV
types were in decreasing order; HPV 51, 18, 59, and 66.
Among 17-year old girls born in 1996, HPV 16, the most com-
mon HPV type, was detected in 2.4% of the samples. After HPV 16,
the four most common high-risk or probable high-risk HPV types
were in decreasing order; HPV 66, 51, 31 and 59.
The prevalence of HPV types deﬁned as undetermined or low-
risk is presented in Fig. 3. For 21-year old women, HPV 90 was the
most common low-risk HPV genotype with a prevalence of 6.4%.
Other common low-risk HPV types were in decreasing order; HPV
42, 87, and 89. The vaccine types HPV 6 and 11 were detected in
3.3% and 0.04% of the 21-year old women, respectively.
Among 17-year old girls born in 1994, the most common low-
risk HPV type was HPV 6 (2.7%), followed by HPV 90, 42, and 87.
The vaccine type HPV 11 was detected in 0.3%.
Among 17-year old girls born in 1996, the most common low-
risk HPV type was HPV 6 (1.8%), followed by HPV90, 89, and 87.
The vaccine type HPV 11 was detected in 0.3%.4. Discussion
This study is the ﬁrst of a series of nationwide, population-
based, cross-sectional studies with the aim to estimate the early
impact of the HPV vaccination program in Norway. We assessed
HPV prevalence in self-sampled urine specimens in 17- and 21-
year old women who have not been offered the vaccine against
HPV as part of the national childhood immunization program.
All the 37 HPV types included in the HPV Luminex assay were
detected in our study sample. Knowledge of the prevalence of
high-risk HPV types 16 and 18 as well as the low-risk HPV types
6 and 11 in the population prior to vaccination is of primary in-
terest for future studies of the impact of the 4-valent vaccine. The
vaccine types HPV16 and 18 were detected in nearly half of the
HPV high-risk positive samples across all age groups, which cor-
respond well with previous results from unvaccinated 20–21 year
old women in Scotland [8]. Of the other vaccine types, HPV 6 was
common, whereas HPV 11 was quite rare. These results are inr 1994 (N¼5468) 17 yr 1996 (N¼5894)
% (95% CI) n % (95% CI)
19.9 (18.8–20.9) 907 15.4 (14.5–16.3)
11.2 (10.3–12.0) 445 7.6 (6.9–8.2)
3.2 (2.7–3.6) 173 2.9 (2.5–3.4)
11.7 (10.9–12.6) 500 8.5 (7.8–9.2)
7.4 (6.7–8.1) 283 4.8 (4.3–5.3)
9.2 (8.5–10.0) 352 6.0 (5.4–6.6)
sted for and those who are HPV type negative, but positive for HPV using generic
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Fig. 2. Prevalence of high-risk and probably high-risk HPV types in urine samples
from unvaccinated Norwegian women by birth cohort.
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Fig. 3. Prevalence of undetermined or low-risk HPV types in urine samples from
unvaccinated Norwegian women by birth cohort.
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of HPV 6 was similar to the prevalence of HPV 11 in a Dutch study
[7].
HPV high-risk types were detected in a large proportion of the
samples and were similar to what has been reported in other
European studies, both regarding types detected and prevalence
[7,8,20]. The prevalence increased with age and was found to be
two- to three times higher in 21-year old women compared to 17-
year olds. Increasing prevalence with age is in line with several
studies [20–23]. All together, these observations conﬁrm that in-
fection with HPV vaccine types or other high-risk types is common
in young Norwegian women.
The HPV prevalence differed between the two birth cohorts of
17-year olds. The prevalence was signiﬁcantly higher among girls
in the 1994 birth cohort as compared to the 1996 birth cohort. The
regional participation pattern was similar in the two birth cohorts
(results not shown), thus regional differences in HPV prevalence
do not explain the difference between these two birth cohorts. The
ﬁnding may be a result of natural ﬂuctuations in the prevalence of
HPV. Also, a few of the participants in the study may have received
the HPV-vaccine outside the national childhood immunization
program. According to data from the Norwegian immunization
register, approximately 3% of all girls born in 1996 and 2% of all
girls born in 1994 have been vaccinated with three doses of the
4-valent vaccine (unpublished data). We do not suspect the small
proportion of individuals in the cohorts already vaccinated to
differentially affect the HPV results. The assumption that the dif-
ference in HPV prevalence between the two cohorts of 17-year
olds is not due to vaccination is supported by the prevalence of
non-vaccine HPV types which is also generally lower in the 1996
birth cohort compared to the 1994 birth cohort.
A major strength of the current study is the population-based
design and large sample. However, the low participation rate may
cause selection bias if willingness to participate is systematically
associated with certain sexual behaviours increasing the risk of
HPV, or vaccination status which would reduce the risk of HPV.
Nevertheless, the aim of the HPV surveillance program is to
monitor changes in prevalence and type distribution over time and
we believe this potential bias to be comparable from year to year,
so the comparison of HPV prevalence's across birth cohorts is still
expected to be valid.
Considering the young age of the study subjects, taking a less
intrusive urine sample is for ethical reasons preferred over a cer-
vical sample.
Testing for HPV in urine samples may not be comparable to
testing cervical smears, as detection of HPV in urine may not be
representative for HPV infections in the cervix. This has been
shown in several studies where in general the HPV prevalence is
lower when HPV DNA is isolated from urine compared to when
HPV DNA is isolated from the cervical smears [8,24]. Accordingly,
the HPV prevalence observed in our study is most likely an un-
derestimate of the true prevalence in cervical specimens. Never-
theless, our large study conﬁrms that HPV testing in urine samples
is easy to implement and highly feasible for epidemiological stu-
dies and vaccine surveillance in young women, as also stated in
other studies [25–28].
Further surveillance of the early impact of the HPV vaccination
program in Norway will include urine samples from both vacci-
nated and not vaccinated birth cohorts. Changes in the HPV pre-
valence over time will be documented. Additionally, the surveil-
lance program is planned to include routine HPV-testing of cer-
vical histological samples with cancerous and pre-cancerous le-
sions. So far, only girls in the 7th grade in Norway has been offered
the HPV vaccine. Thus, it will take several more years before the
vaccine effectiveness including these endpoints can be estimated.5. Conclusions
In conclusion, this large population based study conﬁrms that
HPV testing in urine samples is easy and highly feasible for epi-
demiological studies and vaccine surveillance in young women.
We have assessed the prevalence and genotype distribution of
HPV in urine specimens from young women from a largely un-
vaccinated population, providing important baseline data for early
estimation of the impact of the HPV vaccination program in Nor-
way. HPV was frequently detected. A broad spectrum of HPV types
was identiﬁed and multiple infections were prevalent. HPV was
detected two to three fold more frequently in 21-year old women
compared to 17-year old women, and there were also differences
between the two 17-year old birth cohorts. The vaccine speciﬁc
HPV types 6, 16 and 18 were quite common in young Norwegian
women, whereas the vaccine type HPV 11 was quite rare.Conﬂict of interests
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